Semiconductor device
    121.
    发明授权
    Semiconductor device 有权
    半导体器件

    公开(公告)号:US07773436B2

    公开(公告)日:2010-08-10

    申请号:US12000592

    申请日:2007-12-14

    CPC classification number: G11C5/141 G11C5/142 G11C29/70

    Abstract: An object is to provide a semiconductor device having a memory which can efficiently improve a yield by employing a structure which facilitates the use of a spare memory cell. The semiconductor device includes a memory cell array having a memory cell and a spare memory cell, a decoder connected to the memory cell and the spare memory cell, a data holding circuit connected to the decoder, and a battery which supplies electric power to the data holding circuit. The spare memory cell operates in accordance with an output from the data holding circuit.

    Abstract translation: 目的是提供一种具有存储器的半导体器件,其可以通过采用有利于使用备用存储单元的结构来有效地提高产量。 半导体器件包括具有存储单元和备用存储单元的存储单元阵列,连接到存储单元和备用存储单元的解码器,连接到解码器的数据保持电路以及向数据提供电力的电池 保持电路。 备用存储单元根据数据保持电路的输出进行工作。

    CONDENSED PYRIDINE COMPOUND
    122.
    发明申请
    CONDENSED PYRIDINE COMPOUND 审中-公开
    浓缩的吡啶化合物

    公开(公告)号:US20100105661A1

    公开(公告)日:2010-04-29

    申请号:US12522987

    申请日:2008-01-11

    CPC classification number: C07D471/04 C07D471/14

    Abstract: The present invention provides a compound having excellent JAK3 inhibitory activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases.As a result of investigations with respect to novel condensed heterocyclic derivatives, the inventors have verified that a condensed pyridine compound has excellent JAK3 inhibitory activity, thereby completing the present invention.More specifically, it has been verified that since the compound according to the present invention has inhibitory activity against JAK3, the compound is useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transduction (e.g., rejection during live organ/tissue transplantation, autoimmune diseases, asthma, atopic dermatitis, rheumatism, psoriasis and atherosclerotic disease), or diseases caused by abnormal cytokine signal transduction (e.g., cancer and leukemia).

    Abstract translation: 本发明提供了具有优异的JAK3抑制活性的化合物,可用作治疗和/或预防各种免疫疾病,包括自身免疫性疾病,炎症性疾病和过敏性疾病的药剂的活性成分。 作为关于新的稠合杂环衍生物的研究结果,本发明人证实了缩合的吡啶化合物具有优异的JAK3抑制活性,从而完成了本发明。 更具体地说,由于本发明的化合物对JAK3具有抑制活性,所以该化合物可用作治疗或预防由不良细胞因子信号转导引起的疾病(例如活体排斥)的药剂的有效成分 器官/组织移植,自身免疫疾病,哮喘,特应性皮炎,风湿病,牛皮癣和动脉粥样硬化疾病)或由细胞因子信号转导异常引起的疾病(例如癌症和白血病)。

    Thiazole Derivatives Having Vap-1 Inhibitory Activity
    123.
    发明申请
    Thiazole Derivatives Having Vap-1 Inhibitory Activity 审中-公开
    具有Vap-1抑制活性的噻唑衍生物

    公开(公告)号:US20080015202A1

    公开(公告)日:2008-01-17

    申请号:US11574946

    申请日:2005-09-08

    CPC classification number: C07D417/10 C07D277/46 C07D417/06 C07D417/12

    Abstract: A compound of the formula (I): U-V-W-X-Y-Z  (I) wherein U is lower alkyl; V is —CONH— or —NR1CO— wherein R1 is a hydrogen or lower alkyl; W is a bond or lower alkylene; X is a bivalent residue derived from optionally substituted thiazole; Y is a bond or lower alkylene; and Z is a group of the formula: wherein R2 is a group of the formula: -A-B-D-E-F-G wherein A is a bond or lower alkylene; B is a bond, —NH— or D is a bond, —CS— or —CO—; E is a bond or —NH—; F is a bond, —CO—, —O— or —SO2—; and G is lower alkyl, optionally protected amino, —OH, phenyl, R3 is lower alkyl, provided that when Z is a group of the formula: then G should not be amino, when Z is a group of the formula: then G should not be when Z is a group of the formula: and G is optionally protected amino, then D should be —CS—, or then A should be lower alkylene, B or E should be —NH— and F should be —CO—; or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor as well as a pharmaceutical composition and a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.

    Abstract translation: 式(I)的化合物:<?in-line-formula description =“In-line Formulas”end =“lead”?> UVWXYZ(I)<?in-line-formula description =“In-line Formulas” end =“tail”?>其中U是低级烷基; V是-CONH-或-NR 1 CO-,其中R 1是氢或低级烷基; W是键或低级亚烷基; X是衍生自任选取代的噻唑的二价残基; Y是键或低级亚烷基; 并且Z是下式的基团:其中R 2是下列基团:-A-B-D-E-F-G其中A是键或低级亚烷基; B是键,-NH-或D是键,-CS-或-CO-; E是键或-NH-; F是键,-CO - , - O-或-SO 2 - 。 并且G为低级烷基,任意保护的氨基,-OH,苯基,R 3为低级烷基,条件是当Z为下式基团时,则G不应为氨基,当Z为 组式为:那么G不应该是当Z是下式的基团时:G是任意保护的氨基,那么D应该是-CS-,或者A应该是低级亚烷基,B或E应该是-NH- 而F应为-CO-; 或其药学上可接受的盐可用作血管粘附蛋白-1(VAP-1)抑制剂,以及用于预防或治疗VAP-1相关疾病,特别是黄斑水肿的药物组合物和方法,该方法包括施用有效的 化合物或其药学上可接受的盐对受试者的量等。

    Image acquiring apparatus, image acquiring method, and image acquiring program
    124.
    发明申请
    Image acquiring apparatus, image acquiring method, and image acquiring program 有权
    图像获取装置,图像获取方法和图像获取程序

    公开(公告)号:US20070206105A1

    公开(公告)日:2007-09-06

    申请号:US11477800

    申请日:2006-06-30

    CPC classification number: G02B21/367

    Abstract: An image acquiring apparatus is made up of a macro image acquiring unit 20 used to acquire a macro image of each of a plurality of samples S, and a control unit 60 including a macro image acquisition control unit used to control a macro image acquiring operation and an image pickup condition setting unit used to set an image pickup condition for a micro image of the sample S with reference to the macro image. The control unit 60 includes a session managing unit used to define a session in accordance with a sample group consisting of the samples S and to manage a data group including data of the macro image and the image pickup condition as session data associated with the sample group for each session. According to this structure, it is possible to realize an image acquiring apparatus, an image acquiring method, and an image acquiring program capable of suitably managing image acquisition processing performed to acquire an image of each of a plurality of samples.

    Abstract translation: 图像获取装置由用于获取多个样本S中的每一个的宏图像的宏图像获取单元20和包括用于控制宏图像获取操作的宏图像获取控制单元的控制单元60构成, 图像拾取条件设置单元,用于参考宏图像设置样本S的微图像的图像拾取条件。 控制单元60包括会话管理单元,用于根据由样本S组成的样本组来定义会话,并且将包括宏图像和图像拾取条件的数据组作为与样本组相关联的会话数据进行管理 为每个会话。 根据该结构,可以实现能够适当地管理执行的图像获取装置,图像获取方法和图像获取程序,以获取多个样本中的每一个的图像。

    Resin composition
    129.
    发明授权

    公开(公告)号:US5091473A

    公开(公告)日:1992-02-25

    申请号:US571109

    申请日:1990-08-23

    CPC classification number: C08L77/00 Y10S525/905

    Abstract: There is disclosed a resin composition comprising:(a) 28 to 78% by weight of a polyamide resin,(b) 20 to 70% by weight of a polyphenylene ether resin,(c) 2 to 40% by weight of a block copolymer composed of an alkenyl aromatic polymer and a conjugated diene polymer wherein a content of an alkenyl aromatic polymer structure unit is 10 to 45% by weight and at least 50% of a conjugated diene polymer structure unit is hydrogenated and(d) at least one compound selected from the group consisting of .alpha.,.beta.-unsaturated dicarboxylic acid, an acid anhydride and derivatives thereof with an amount of 0.01 to 10 parts by weight based on 100 parts by weight of the sum of Components (a), (b) and (c),which has a specific dispersion state.The resin composition has excellent thermal stability and also good balance between impact strength, rigidity and high temperature rigidity with high degree.

    Process of purifying maleic anhydride-modified polyolefin
    130.
    发明授权
    Process of purifying maleic anhydride-modified polyolefin 失效
    纯化马来酸酐改性聚烯烃的方法

    公开(公告)号:US4698395A

    公开(公告)日:1987-10-06

    申请号:US863191

    申请日:1986-05-14

    CPC classification number: C08F8/46 C08F255/00 C08F6/06 C08F8/44

    Abstract: A process of purifying maleic anhydride graft polyolefin comprising the steps of adding an aqueous solution of alkali initial hydroxide to a solution of maleic anhydride graft polyolefin containing unreacted maleic anhydride which is dissolved in an organic solvent at a temperature from 80.degree. C. to 160.degree. C., thereby precipitating maleic anhydride graft polyolefin particles to make a W/O emulsion; stirring the W/O emulsion while maintaining the temperature at a same temperature as above for less than 2 hours, thereby selectively forming the alkali metal salt of unreacted maleic anhydride; adding the aqueous solution of alkali metal hydroxide to the W/O emulsion to convert the W/O emulsion into an O/W emulsion; separating the maleic anhydride draft polyolefin particles, and washing the maleic anhydride graft polyolefin particles with water.

    Abstract translation: 一种纯化马来酸酐接枝聚烯烃的方法,包括以下步骤:将碱初始氢氧化物水溶液加入到含有未反应的马来酸酐的马来酸酐接枝聚烯烃溶液中,所述马来酸酐接枝聚烯烃在80℃至160℃的温度下溶解在有机溶剂中 从而沉淀马来酸酐接枝聚烯烃颗粒以制备W / O乳液; 搅拌W / O乳液同时将温度保持在与上述相同的温度下少于2小时,从而选择性地形成未反应的马来酸酐的碱金属盐; 将碱金属氢氧化物水溶液加入到W / O乳液中以将W / O乳液转化为O / W乳液; 分离马来酸酐卷曲聚烯烃颗粒,并用水洗涤马来酸酐接枝聚烯烃颗粒。

Patent Agency Ranking